All In Biotech

Drug Trial Radar · NCT03001544

Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer

Phase 1 Single-ascending Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Anti-alpha2-antiplasmin (α2AP) Monoclonal Antibody TS23 in Healthy Human Volunteers

Last checked: Nov 19, 2026Latest source record: Dec 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

24

Actual

Start

Jul 2015

Primary completion

Jun 2016

Study completion Jun 2017

Sponsor

Lead sponsor
Translational Sciences, Inc.Industry
Sponsor type
Industry
First posted
Dec 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to determine the safety, pharmacokinetics and pharmacodynamics of a single intravenous dose of TS23 in healthy adults.

Conditions

  • Thrombosis
  • Cerebral Ischemia
  • Venous Thrombosis
  • Pulmonary Embolism
  • Myocardial Infarction

Interventions

  • TS23Biological

    comparison of different doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and severity of adverse events post-doseTime frame: 10 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.